Optimising the management of peanut allergy by targeting immune plasticity
Authors:
Open Access
- 29 February 2024
- journal article
- review article
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (3) , 169-184
Abstract
Randomised controlled trials investigating the efficacy of oral tolerance induction to peanut have enabled detailed comparison of their clinical and immunological success. They have demonstrated that the regular consumption of peanut for at least 2 years by babies who are not allergic enables protection from developing peanut allergy. The LEAP study intervention tested the impact of regular peanut consumption for 4 years and demonstrated a sustained protection against the development of peanut allergy even after 12 months of peanut avoidance from 5 to 6 years of age. The PreventADALL trial introduced multiple allergens into babies' diets from early infancy and reduced the prevalence of food allergy at 3 years, especially by protecting against peanut allergy. Immunological studies from the LEAP cohort demonstrated that regular peanut consumption was associated with a prompt induction of peanut‐specific IgG4 and reduced manufacture of peanut and Ara h 2‐specific IgE. Even after stopping peanut consumption for 5 years, there continued to be a significant fall in peanut‐specific Ara h 2 IgE in the consumption group from 5 to 6 years of age (p < .01). Children who developed peanut allergy by 5 years started to develop increasing sensitisation to linear sequential peanut epitopes from 2.5 years of age, suggesting that putative disease‐modifying interventions should commence before 3 years. Data comparing clinical outcomes between children undergoing peanut immunotherapy from infancy suggest that younger children can consume higher portions of peanut without reaction on challenge whilst taking immunotherapy, have fewer side effects and are more likely to enjoy remission of PA. Peanut oral immunotherapy modulates T‐cell populations in order to bring about hypo‐responsiveness of allergy effector cells. Studies are now needed to characterise and compare different states of immunological tolerance. This will accelerate the design of interventions which can promote primary, secondary and tertiary levels of PA prevention across a range of age groups.Keywords
This publication has 62 references indexed in Scilit:
- Timing of Allergenic Food Introduction and Risk of Immunoglobulin E–Mediated Food AllergyJAMA Pediatrics, 2023
- A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic IndividualseClinicalMedicine, 2019
- Immune mechanisms of food allergy and its prevention by early interventionCurrent Opinion in Immunology, 2017
- Immunology of Food AllergyImmunity, 2017
- Update on risk factors for food allergyJournal of Allergy and Clinical Immunology, 2012
- The gut as communicator between environment and host: Immunological consequencesEuropean Journal of Pharmacology, 2011
- Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infantsJournal of Allergy and Clinical Immunology, 2011
- Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergyJournal of Allergy and Clinical Immunology, 2011
- Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel ReportJournal of Allergy and Clinical Immunology, 2010
- Clinical efficacy and immune regulation with peanut oral immunotherapyJournal of Allergy and Clinical Immunology, 2009